chemXplore tracks 14 projects in Taiwan, of which 11 are active.
Of the active ones, 5 new construction, 4 expansion and 2 revamp / retrofit.
5 active projects carry no start-up date yet. The dates themselves, per project, are for subscribers.
Adds production capacity, boosts Innovation Center and analytical capabilities to support advanced nodes, improve supply‑chain resilience and speed customer support.
Collaboration produced a battery pack concept mockup shown at the 2026 Paris Motor Show; next step is a functional battery segment to test thermal management and cell integration.
Introduces a Dynamic Coordination Network using a Superfluidized Inorganic Electrolyte to enable a third ion‑transport mode and fast‑charging automotive applications.
Post‑hoc ATTAIN‑1 modelling: oral orforglipron cut predicted 10‑year type 2 diabetes risk up to 57% and cardiovascular risk up to 18% versus placebo at 72 weeks.
EU launches anti-dumping probe after PVC imports doubled in 12 months; industry urges faster provisional measures, safeguards and more DG Trade resources to protect European production.
Phase‑1 ready oral GLP‑1/GIP dual agonist with up to $2.6bn deal value including $300m upfront; development and commercial rights exclude Greater China.
An indirect, covariate‑adjusted comparison of SURMOUNT‑1 and STEP UP data shows larger mean and categorical weight‑loss benefits with tirzepatide 10 mg and 15 mg at 72 weeks.
BLA for I‑DXd seeking accelerated approval in extensive‑stage SCLC withdrawn after FDA said Phase 2 data were insufficient; Phase 3 programmes continue.
Priority access to a new Gen4 inorganic solid‑state cell; Mercedes will run electrical, thermal and safety trials to assess suitability for future EV platforms.
FDA clears once‑weekly basal insulin that reduces injection frequency vs daily therapy; Phase 3 QWINT trials in >3,400 adults showed non‑inferior A1C vs glargine and degludec.
